Evidence map›Paper›PMID 42141708›Full record

ArticleCancer medicine2026

DEC1 Deficiency Attenuates Breast Cancer-Induced Osteolytic Destruction by Suppression of Cancer-Associated Fibroblast Differentiation.

Zhiyi Qiang, Ying Huo, Lan Lin, Kaiao Chen, Wei Liu, Jian Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiyi QiangDepartment of Pharmacology, Nanjing Medical University, Nanjing, China.
Ying HuoDepartment of Pharmacology, Nanjing Medical University, Nanjing, China.
Lan LinDepartment of Pharmacology, Nanjing Medical University, Nanjing, China.
Kaiao ChenDepartment of Pharmacology, Nanjing Medical University, Nanjing, China.
Wei LiuDepartment of Pharmacology, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-5049-2723
Jian YangDepartment of Pharmacology, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0003-2590-2388

Funding

National Natural Science Foundation of China 81872937National Natural Science Foundation of China 82073934
6 · The paper itself

Abstract

backgroundCancer-associated fibroblasts (CAFs) in the bone microenvironment play a key role in breast cancer (BC) osteolytic bone metastases. Differentiated embryo-chondrocyte expressed gene 1 (DEC1) has been implicated as a potential therapeutic target in CAFs. Here, we investigate the role of DEC1 within the bone microenvironment during BC cell-induced bone destruction.

methodsIn vivo, a BC bone metastasis mouse model by intratibially injecting 4 T1 cells into DEC1

resultsDEC1 deficiency markedly attenuated BC-induced osteolytic destruction. Notably, DEC1

conclusionOur findings demonstrate that DEC1 deficiency in the bone microenvironment critically restrains BC cell-induced bone destruction through inhibition of CAF differentiation.

Indexed as

Basic Helix-Loop-Helix ProteinsBone NeoplasmsBreast NeoplasmsCancer-Associated FibroblastsOsteolysisAnimalsCell DifferentiationCell Line, TumorDisease Models, AnimalFemaleHomeodomain ProteinsHumansInterleukin-6Janus Kinase 2Mesenchymal Stem CellsMiceBasic Helix-Loop-Helix ProteinsBhlhe40 protein, mouseHomeodomain ProteinsInterleukin-6Jak2 protein, mouseJanus Kinase 2RANK LigandStat3 protein, mouseSTAT3 Transcription Factorbreast cancer induced osteolytic destructioncancer‐associated fibroblasts (CAFs)differentiated embryonic chondrocyte expressed gene 1 (DEC1)JAK2/STAT3

Identifiers

PMID42141708
PMCPMC13179420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.